The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 901–1,000 of 1,025
Neuroprotective Mechanisms Mediated by CDK5 Inhibition
Mushtaq, G., Greig, N. H., Anwar, F., Al-Abbasi, F. A., Zamzami, M. A., Al-Talhi, H. A., & Kamal, M. A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151124235028 · Cited by 66
Prevention and Treatment of Alzheimer’s Disease: Biological Mechanisms of Exercise
McGurran, H., Glenn, J. M., Madero, E. N., & Bott, N. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180958 · Cited by 63
Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia
Iráizoz, I., Guijarro, J. L., Gonzalo, L. M., & Lacalle, S. D. (1999) · Acta Neuropathologica · doi:10.1007/s004010051068 · Cited by 61
Feczko, E., Augustinack, J. C., Fischl, B. R., & Dickerson, B. C. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.023 · Cited by 63
von Gunten, A., Ebbing, K., Imhof, A., Giannakopoulos, P., & Kövari, E. (2010) · Current Gerontology and Geriatrics Research · doi:10.1155/2010/358531 · Cited by 62
Edwards, L., Joie, R. L., Iaccarino, L., Strom, A., Baker, S. L., Casaletto, K. B., Cobigo, Y., Grant, H. E., Kim, M., Kramer, J. H., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.003 · Cited by 65
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Alzheimer disease without neocortical neurofibrillary tangles
Tiraboschi, P., Sabbagh, M. N., Hansen, L. A., Salmon, D. P., Merdes, A., Gamst, A. C., Masliah, E., Alford, M. F., Thal, L. J., & Corey‐Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000118212.41542.e7 · Cited by 62
Royall, D. R., Gao, J., & Kellogg, D. L. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.10.036 · Cited by 62
Calpain Dysregulation in Alzheimer’s Disease
Ferreira, A. (2012) · ISRN Biochemistry · doi:10.5402/2012/728571 · Cited by 64
Ferman, T. J., & Boeve, B. F. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.001 · Cited by 68
PET imaging of tau protein targets: a methodology perspective
Lois, C., González, I., Johnson, K. A., & Price, J. C. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9847-7 · Cited by 64
Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles
Lauckner, J., Frey, P., & Geula, C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00228-2 · Cited by 61
Comparison of New Tau PET-Tracer Candidates With [ 18 F]T808 and [ 18 F]T807
Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcázar, J., Ariza, M., Fierens, K., Bottelbergs, A., et al. (2016) · Molecular Imaging · doi:10.1177/1536012115624920 · Cited by 63
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 59
Zeng, L., Jiang, H., Ashraf, G. M., Liu, J., Wang, L., Zhao, K., Liu, M., Li, Z., & Liu, R. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.11.019 · Cited by 61
Ocular Surface Management of Photorefractive Keratectomy and Laser in situ Keratomileusis
Albietz, J., McLennan, S. G., & Lenton, L. M. (2003) · Journal of Refractive Surgery · doi:10.3928/1081-597x-20031101-05 · Cited by 61
Blalock, E. M., Grondin, R., Chen, K.-C., Thibault, O., Thibault, V., Pandya, J. D., Dowling, A. L. S., Zhang, Z., Sullivan, P. G., Porter, N. M., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3956-09.2010 · Cited by 61
The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain
McDonald, J. M., Cairns, N. J., Taylor‐Reinwald, L., Holtzman, D. M., & Walsh, D. M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.02.041 · Cited by 61
Tyrosine Nitration within the Proline-Rich Region of Tau in Alzheimer's Disease
Reyes, J. F., Fu, Y., Vana, L., Kanaan, N. M., & Binder, L. I. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.030 · Cited by 61
Visual search in Alzheimer’s disease: a deficiency in processing conjunctions of features
Tales, A., Butler, S. R., Fossey, J., Gilchrist, I. D., Jones, R. W., & Troscianko, T. (2002) · Neuropsychologia · doi:10.1016/s0028-3932(02)00073-8 · Cited by 61
Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial
Iqbal, K., Wang, X., Blanchard, J., Liu, F., Gong, C., & Grundke, I. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380962 · Cited by 61
Rodríguez, L. C. D. L. C., Mohamed, N., Desjardins, A., Lippé, R., Fon, E. A., & Leclerc, N. M. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13994 · Cited by 66
Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation
Reilly, P., Winston, C. N., Baron, K. R., Trejo, M., Rockenstein, E. M., Akers, J. C., Kfoury, N., Diamond, M. I., Masliah, E., Rissman, R. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.005 · Cited by 61
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62
Zhang, Q., Xia, Y., Luo, H., Huang, S., Wang, Y., Shentu, Y., Mahaman, Y. A. R., Huang, F., Ke, D., Wang, Q., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00437 · Cited by 61
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach
Iqbal, K., del Alonso, A. C., Gondal, J. A., Gong, C., Haque, N., Khatoon, S., Sengupta, A., Wang, J.-Z., & Grundke, I. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_22 · Cited by 60
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Félician, O., & Sandson, T. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.1.19 · Cited by 61
Giannakopoulos, P., Hof, P. R., Surini, M., Michel, J., & Bouras, C. (1993) · Acta Neuropathologica · doi:10.1007/bf00334669 · Cited by 61
Microglia: Friend and foe in tauopathy
Odfalk, K. F., Bieniek, K. F., & Hopp, S. C. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102306 · Cited by 60
Tangles, Toxicity, and Tau Secretion in AD – New Approaches to a Vexing Problem
Gendreau, K. L., & Hall, G. F. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00160 · Cited by 67
Lumsden, A. L., Rogers, J. T., Majd, S., Newman, M., Sutherland, G. T., Verdile, G., & Lardelli, M. T. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00533 · Cited by 60
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi‐Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 63
Patel, H., Martínez, P., Perkins, A., Taylor, X., Jury, N., McKinzie, D. L., & Lasagna‐Reeves, C. A. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.006 · Cited by 58
Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models
Acker, C. M., Forest, S. K., Zinkowski, R., Davies, P., & d’Abramo, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.010 · Cited by 59
Arnold, S. E., Toledo, J. B., Appleby, D. H., Xie, S. X., Wang, W., Baek, Y., Wolk, D. A., Lee, E. B., Miller, B. L., Lee, V. M. ‐., et al. (2013) · The Journal of Comparative Neurology · doi:10.1002/cne.23430 · Cited by 66
Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 62
Coniferaldehyde attenuates Alzheimer's pathology via activation of Nrf2 and its targets
Dong, Y., Stewart, T., Bai, L., Li, X., Xu, T., Iliff, J. J., Shi, M. Y., Zheng, D., Yuan, L., Wei, T., et al. (2019) · Theranostics · doi:10.7150/thno.36722 · Cited by 60
Apolipoprotein E and Alzheimer's Disease: A Review of Recent Studies
Higgins, G. A., Large, C. H., Rupniak, H. T., & Barnes, J. C. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00420-0 · Cited by 58
Tau Function and Dysfunction in Neurons
Ávila, J., Lim, F., Moreno, F. J., Belmonte, C., & Cuello, A. C. (2002) · Molecular Neurobiology · doi:10.1385/mn:25:3:213 · Cited by 63
Neurotrophin receptor p75 mediates amyloid β-induced tau pathology
Shen, L.-L., Li, W.-W., Xu, Y.-L., Gao, S.-H., Xu, M.-Y., Bu, X.-L., Liu, Y.-H., Wang, J., Zhu, J., Zeng, F., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104567 · Cited by 59
Paley, E. L., Denisova, G. F., Sokolova, O. S., Posternak, N., Wang, X., & Brownell, A. (2006) · NeuroMolecular Medicine · doi:10.1385/nmm:9:1:55 · Cited by 58
Guzmán, B. C., Chaffey, T. E., Palpagama, T. H., Waters, S., Boix, J., Tate, W. P., Peppercorn, K., Dragunow, M., Waldvogel, H. J., Faull, R. L. M., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.552073 · Cited by 63
Guennewig, B., Lim, J., Marshall, L. L., McCorkindale, A. N., Paasila, P. J., Patrick, E., Kril, J. J., Halliday, G. M., Cooper, A. A., & Sutherland, G. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-83872-z · Cited by 59
Berberine Attenuates Calyculin A-Induced Cytotoxicity and Tau Hyperphosphorylation in HEK293 Cells
Yu, G., Li, Y., Tian, Q., Liu, R., Wang, Q., Wang, J., & Wang, X. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101779 · Cited by 59
Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 60
Tau Phosphorylation, Aggregation, and Cell Toxicity
Ávila, J., Santa‐María, I., Pérez, M., Hernández, F., & Moreno, F. J. (2006) · BioMed Research International · doi:10.1155/jbb/2006/74539 · Cited by 62
Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities
Koppel, J. L., Acker, C., Davies, P., López, O. L., Jimenez, H. T., Azose, M., GREENWALD, B. S., Murray, P. S., Kirkwood, C. M., Kofler, J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.003 · Cited by 60
Developing therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
Okuda, M., Fujita, Y., Hijikuro, I., Wada, M., Uemura, T., Kobayashi, Y., Waku, T., Tanaka, N., Nishimoto, T., Izumi, Y., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161017 · Cited by 59
Cullen, K. M., & Halliday, G. M. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00066-9 · Cited by 59
Pathologic Correlates of Apraxia in Alzheimer Disease
Giannakopoulos, P., Duc, M., Gold, G., Hof, P. R., Michel, J., & Bouras, C. (1998) · Archives of Neurology · doi:10.1001/archneur.55.5.689 · Cited by 58
Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology
Jonasson, M., Wall, A. E., Chiotis, K., Saint‐Aubert, L., Wilking, H., Sprycha, M., Borg, B., Thibblin, A., Eriksson, J., Sørensen, J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158519 · Cited by 59
Tau-related white-matter alterations along spatially selective pathways
Wen, Q., Risacher, S. L., Xie, L., Li, J., Harezlak, J., Farlow, M. R., Unverzagt, F. W., Gao, S., Apostolova, L. G., Saykin, A. J., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117560 · Cited by 60
The AD tau core spontaneously self-assembles and recruits full-length tau to filaments
Carlomagno, Y., Manne, S., Deture, M. A., Prudencio, M., Zhang, Y., Al‐Shaikh, R. H., Dunmore, J. A., Daughrity, L. M., Song, Y., Castanedes‐Casey, M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108843 · Cited by 59
Balducci, C., Mehdawy, B., Mare, L., Giuliani, A., Lorenzini, L., Sivilia, S., Giardino, L., Calzà, L., Lanzillotta, A., Sarnico, I., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101839 · Cited by 58
Yu, Y., Li, X., Blanchard, J., Li, Y., Iqbal, K., Liu, F., & Gong, C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1294-z · Cited by 60
Amygdalar Atrophy in Early Alzheimer’s Disease
Klein, Y., Heckemann, R. A., Ramdeen, K. T., Moreaud, O., Keignart, S., Krainik, A., Hammers, A., Baciu, M., Hot, P., & Initiative, A. D. N. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140131123653 · Cited by 57
Wang, Y., Ren, Q., Gong, W.-G., Wu, D., Tang, X., Li, X.-L., Wu, F., Bai, F., Xu, L., & Zhang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.7798 · Cited by 60
Negative Symptoms in Patients With Alzheimer's Disease
GALYNKER, I. I., Roane, D. M., Miner, C. R., Feinberg, T. E., & Watts, P. (1995) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199524310-00007 · Cited by 60
Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions
Arnold, S. E., Franz, B. R., & Trojanowski, J. Q. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90024-8 · Cited by 58
NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex
Carlson, M. D., Penney, J. B., & Young, A. B. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90120-z · Cited by 58
Practical measures to simplify the Braak tangle staging method for routine pathological screening
Harding, A. J., Kril, J. J., & Halliday, G. M. (2000) · Acta Neuropathologica · doi:10.1007/pl00007425 · Cited by 58
Alzheimer’s disease brain contains tau fractions with differential prion-like activities
Li, L., Shi, R., Gu, J., Tung, Y. C., Zhou, Y., Zhou, D., Wu, R., Chu, D., Jin, N., Deng, K., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01127-4 · Cited by 60
Prospects for delaying the rising tide of worldwide, late-life dementias
Larson, E. B. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210001080 · Cited by 60
Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Hahn, A., Schain, M., Erlandsson, M., Sjölin, P., James, G. M., Strandberg, O. T., Hägerström, D., Lanzenberger, R. R., Jögi, J., Olsson, T. G., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174508 · Cited by 57
Bangen, K. J., Clark, A. L., Edmonds, E. C., Evangelista, N. D., Werhane, M. L., Thomas, K. R., Locano, L. E., Tran, M., Zlatar, Z. Z., Nation, D. A., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00181 · Cited by 61
KrishnaKumar, V. G., Paul, A., Gazit, E., & Segal, D. (2018) · Scientific Reports · doi:10.1038/s41598-017-18443-2 · Cited by 57
Pathogenesis of Alzheimer's Disease: Role of Amyloid-beta and Hyperphosphorylated Tau Protein
Sajjad, R., Arif, R., Shah, A. A., Manzoor, I., & Mustafa, G. (2018) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000397 · Cited by 57
Tian, Q., Lin, Z.-Q., Wang, X., Chen, J., Wang, Q., Gong, C., & Wang, J. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.03.037 · Cited by 57
Lu, M., Pontecorvo, M. J., Devous, M. D., Arora, A. K., Galante, N., McGeehan, A., Devadanam, C., Salloway, S. P., Doraiswamy, P. M., Curtis, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5505 · Cited by 56
Yin, Y., Liu, H., Cong, X.-B., Liu, Z., Wang, Q., Wang, J., & Zhu, L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1272 · Cited by 56
Optical coherence tomography visualizes neurons in human entorhinal cortex
Magnain, C. V., Augustinack, J. C., Konukoğlu, E., Frosch, M. P., Sakadžić, S., Michaud, A., Garcia, N., Wedeen, V. J., Boas, D. A., & Fischl, B. R. (2015) · Neurophotonics · doi:10.1117/1.nph.2.1.015004 · Cited by 56
Ramachandran, G., & Udgaonkar, J. B. (2013) · Biochemistry · doi:10.1021/bi400209z · Cited by 59
The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia
Gordon, B. A., Najmi, S., Hsu, P. J., Roe, C. M., Morris, J. C., & Benzinger, T. L. S. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.04.017 · Cited by 62
Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease
Serrano‐Pozo, A., Mielke, M. L., Muzitansky, A., Gómez‐Isla, T., Growdon, J. H., Bacskai, B. J., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825e77de · Cited by 57
Self-citationMechanisms of Tau Self-Aggregation and Neurotoxicity
Farias, G. A., Cornejo, A., Jimenez, J., Guzmán, L., & Maccioni, R. B. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717258 · Cited by 55
Michalski, B., Corrada, M. M., Kawas, C. H., & Fahnestock, M. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.022 · Cited by 57
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Roe, C. M., Ghoshal, N., Morris, J. C., Cairns, N. J., & Kukull, W. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d7a1 · Cited by 57
Early Diagnosis of Alzheimer’s Disease
Daffner, K. R., & Scinto, L. F. M. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_1 · Cited by 56
Chan, A. S., Salmon, D. P., Butters, N., & Johnson, S. A. (1995) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617700000291 · Cited by 61
Relatively Preserved Hippocampal Glucose Metabolism in Mild Alzheimer’s Disease
Ishii, K., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., & Mori, E. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017083 · Cited by 56
Yamaguchi, H., Sugihara, S., Ogawa, A., Oshima, N., & Ihara, Y. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.7.731 · Cited by 56
Regulation of Caspases in the Nervous System
Troy, C. M., Akpan, N., & Jean, Y. Y. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385504-6.00007-5 · Cited by 58
Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model
Helboe, L., Egebjerg, J., Barkholt, P., & Volbracht, C. (2017) · Brain Research · doi:10.1016/j.brainres.2017.04.002 · Cited by 56
Ballesteros‐Álvarez, J., Nguyen, W., Sivapatham, R., Rane, A., & Andersen, J. K. (2022) · GeroScience · doi:10.1007/s11357-022-00708-y · Cited by 60
Regional alteration of synapsin I in the hippocampal formation of Alzheimer?s disease patients
Song, Q., Hu, X., Xu, H., & Zhou, J. (2004) · Acta Neuropathologica · doi:10.1007/s00401-003-0800-4 · Cited by 55
Moreno‐Herrero, F., Pérez, M., Baró, A. M., & Ávila, J. (2004) · Biophysical Journal · doi:10.1016/s0006-3495(04)74130-2 · Cited by 55
Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129003 · Cited by 57
Scarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 55
Cortical biochemistry in MCI and Alzheimer disease
Forman, M. S., Mufson, E. J., Leurgans, S. E., Praticò, D., Joyce, S. C., Leight, S., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Neurology · doi:10.1212/01.wnl.0000256373.39415.b1 · Cited by 54
From genetics to pathology: tau and a–synuclein assemblies in neurodegenerative diseases
Goedert, M., Spillantini, M. G., Serpell, L. C., Berriman, J. A., Smith, M. J., Jakes, R., & Crowther, R. A. (2001) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2000.0767 · Cited by 57
Apolipoprotein E Genotype and Deposits of Aβ40 and Aβ42 in Alzheimer Disease
McNamara, M. J., Gómez‐Isla, T., & Hyman, B. T. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.1001 · Cited by 55
Self-citationA multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease
Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54
Self-citationImpact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Kim, H., Jin, J.-J., Maxwell, J. A., & Fukuchi, K.-I. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.06.006 · Cited by 55
Jiang, J., Wang, Z.-H., Qu, M., Gao, D., Liu, X.-P., Zhu, L., & Wang, J. (2015) · Scientific Reports · doi:10.1038/srep11765 · Cited by 57
Lathuilière, A., Valdés, P., Papin, S., Cacquevel, M., Maclachlan, C., Knott, G. W., Muhs, A., Paganetti, P., & Schneider, B. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-13786-2 · Cited by 57
Panda, C., Voelz, C., Habib, P., Mevissen, C., Pufe, T., Beyer, C., Gupta, S. K., & Slowik, A. (2021) · Cells · doi:10.3390/cells10071652 · Cited by 54
Tau acts as a mediator forAlzheimer's disease‐related synaptic deficits
Liao, D., Miller, E. C., & Teravskis, P. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12504 · Cited by 53
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
